2001
DOI: 10.1006/bbrc.2001.5056
|View full text |Cite
|
Sign up to set email alerts
|

Influence of Degradation on Binding Properties and Biological Activity of Endomorphin 1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
14
0

Year Published

2002
2002
2014
2014

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 22 publications
(14 citation statements)
references
References 30 publications
0
14
0
Order By: Relevance
“…1 The C-terminal L-Phe in endomorphin-2 appears to generate the optimum µ receptor binding activity; however, D-Phe 4 and des-Phe 4 derivatives provided only a little lower affinity. 17,25,29 The negative impact of the Nterminal D-Tyr on µ affinity was found to be minimal. However, Phe 3 residue was quite essential, because its enantiomer reduced the µ affinity.…”
Section: Introductionmentioning
confidence: 92%
“…1 The C-terminal L-Phe in endomorphin-2 appears to generate the optimum µ receptor binding activity; however, D-Phe 4 and des-Phe 4 derivatives provided only a little lower affinity. 17,25,29 The negative impact of the Nterminal D-Tyr on µ affinity was found to be minimal. However, Phe 3 residue was quite essential, because its enantiomer reduced the µ affinity.…”
Section: Introductionmentioning
confidence: 92%
“…Because of structural similarities to the parent compound, the degradation products might compete with endomorphins for the receptor binding site and could influence their biological activity. However, Szatmari et al (2001) demonstrated that the primary degradation products of endomorphin-1, Tyr-Pro-Trp-Phe-OH and Pro-Trp-Phe-OH, possess low -opioid receptor binding affinity, do not activate G-proteins and have no antinociceptive activity.…”
Section: Enzymatic Degradationmentioning
confidence: 99%
“…Particularly, the rewarding effect of EMs can be separated from analgesia (Wilson et al, 2000), and they are less prone to induce respiratory depression and cardiovascular effects (Czapla et al, 2000), opening the possibility of pharmaceutical uses of EMs. They are also model peptides to determine the structure-activity relationship based on their typical characteristics of backbones and aromatic side chains (Szatmári et al, 2001;Okada et al, 2003).…”
Section: Introductionmentioning
confidence: 99%